x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

science life sciences

All Episodes

00:10:35

Jun 16, 2026 | BridgeBio BBP-418 Sweeps LGMD Phase 3;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/17

BridgeBio's BBP-418 sweeps Phase 3 in limb-girdle muscular dystrophy — stock up 15%, no approved competition. FDA briefing docs challenge Moderna mFlusiva efficacy ahead of Thursday's VRBPAC vote. Plus Lilly acquires non-opioid pain startup 4E Therapeutics, Edgewise advances EDG-7500 toward Phase 3 in HCM, and Neumora abandons navacaprant after two Phase 3 failures.Visit www.thepharmacloseput.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The

en-us

00:10:21

Jun 15, 2026 | CMS Targets SubQ Keytruda and Opdivo...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/16

CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS vaccine crashes, and FDA approves Truqap in prostate cancer and Tzield for pediatric T1D.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, CMS, Medicare drug price negotiation,

en-us

00:20:12

EHA 2026 Special — Full Meeting Recap

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/15

The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-published; ~73% dysgeusia the caveat.AML: the menin inhibitor frontline class war — ziftomenib KOMET-007 (CRc 96% NPM1m / 90%KMT2Ar) vs revumenib (frontline CRc 97%; SAVE ORR 88%) — and the gilteritinib-vs-midostaurin FLT3 survival miss (HR 1.02). CLL: BRUIN CLL-322 —

en-us

00:13:46

Jun 12, 2026 | FDA Approves Merck Welireg-Keytruda...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/13

FDA approves Merck's Welireg-Keytruda combo for adjuvant kidney cancer — 28% risk reduction vs. active Keytruda monotherapy in LITESPARK-022. Jazz's Zepzelca misses OS endpoint in Phase 3 LAGOON, Incyte acquires Vega Therapeutics for $1.25B, and Amgen files independent Duke review to fight FDA's proposed Tavneos withdrawal.pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Merck, Keytruda, Welireg, belzutifan, pembrolizumab, kidney

en-us

00:10:01

Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/12

Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering, and Genentech reshapes its research organization.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, zasocitinib, Takeda, Sotyktu, deucravacitinib, Bristol Myers Squibb, TYK2,

en-us

00:25:56

ADA 2026 Special: The full recap

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/11

The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ended the A1C-only era and reset what obesity medicine can do. Hosts Alex Mercer and Maya Patel walk every major readout, with the commercial read on each.Visit us at www.thepharmacloseout.comADA 2026, American DiabetesAssociation, diabetes, obesity, GLP-1, retatrutide, orforglipron, tirzepatide, semaglutide, CagriSema, survodutide, MASH, type 1

en-us

00:09:44

un 10, 2026 | Parabilis Sets Record $670M Biotech...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/11

Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis data. AstraZeneca's oral GLP-1 elecoglipron hits 11.8% weight loss.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Parabilis Medicines, biotech IPO, zolucatetide, TG

en-us

00:18:06

The AI Vendor Draft — How Big Pharma Picked Its AI...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/08

In about six weeks this spring, four of the biggest names in pharma each picked an AI partner — Bristol Myers Squibb chose Anthropic's Claude for 30,000+ employees, Merck signed with Google Cloud for up to $1B, Novo Nordisk went with OpenAI, and Eli Lilly built what NVIDIA calls the industry's most powerful AI supercomputer. A Pharma Closeout Special Report, fact-checked against the primary company and FDA releases, on what they actually bought — and who's likely to be proven right.Visit

en-us

00:11:21

Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/08

Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.

en-us

00:10:57

Jun 04, 2026 | SCOTUS Backs Hikma Skinny-Label Win on...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/05

SCOTUS unanimously backs Hikma's skinny-label Vascepa generic, reshaping patent defense for branded pharma. ADC Therapeutics drops 50%+ on LOTIS-5 death rate (13.2% vs 4.6%), biotech M&A crosses $106B in 2026, and Legend Biotech surges on in vivo CAR-T data.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Hikma, Amarin, Vascepa, skinny label, Supreme Court, generics, ADC Therapeutics,

en-us

00:18:40

ASCO 2026 Special, Part 2 — ThClosing Days: Iza-bren...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/03

Part 2 of The Pharma Closeout's ASCO 2026 special covers the closing days, MondayJune 1 and Tuesday June 2 — net-new readouts plus resolution of Part 1's June 1-2 watch-list. HEADLINE: izalontamab brengitecan (iza-bren), an EGFR-directed bispecificADC, hits dual PFS+OS endpoints in pretreated TNBC (OS HR 0.60, PFS HR 0.29, ORR 52% vs 21%) and again in 2L esophageal squamous cancer (OS HR 0.64).BREAST: persevERA misses (giredestrant+palbociclib, HR 0.89, p=0.16); SERENA-6 final PFS2

en-us

00:27:30

ASCO 2026 Special — Comprehensive Opening Weekend:...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/01

ASCO 2026 comprehensive opening-weekend recap (28 readouts through Sunday, May 31). Headline: Revolution Medicines' RASolute 302 doubles overall survival in second-line pancreatic cancer (daraxonrasib, 13.2 vs 6.7months, HR 0.40). LUNG: CROWN 7-year (lorlatinib 55% vs 3% PFS), LIBRETTO-432 adjuvant selpercatinib (83% reduction), WU-KONG28 sunvozertinib, HARMONi-6ivonescimab (34% OS, soft reaction), OptiTROP-Lung05 sac-TMT (PFS HR 0.35), plus ROSETTA Lung-02, CHRYSALIS-2, Krascendo-170,

en-us

00:11:58

May 31, 2026 | ASCO 2026: Revolution Medicines...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/06/01

RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Plus ivonescimab's 34% OS improvement with caveats,Pfizer-Innovent's $10.5B deal for 12 cancer programs, and GSK/Ionis's buried hepatitis B 'functional cure.'Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:08:54

May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/30

Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Phase 3 for Pomalyst successor mezigdomide at ASCO 2026. Merck, Agios, MannKind, and PDUFA reauthorization round out a packed Friday.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Innovent Biologics, Bristol Myers Squibb, mezigdomide,

en-us

00:10:34

May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19%...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/29

Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio LGMD data, Kardigan IPO plans, and ASCO 2026 abstracts drop.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, bepirovirsen, GSK, Ionis, hepatitis B,

en-us

00:10:30

May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/21

Pfizer's 25-valent pneumococcal shot shows 8.8x–15x higher antibody levels vs. Prevnar 20 in Phase 2, advancing to Phase 3. BMS deploys Claude across 30,000+ employees in landmark pharma-AI deal. Lilly acquires Engage Bio for $202M. Tavneos linked to 20 deaths in Japan.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Prevnar 20, 25vPnC, pneumococcal vaccine, Bristol Myers Squibb, BMS,

en-us

00:11:13

May 19, 2026 | Takeda $885M Antitrust Verdict;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/21

Takeda hit with $885M pay-for-delay verdict over generic Amitiza delay. UCB's Bimzelx beats AbbVie's Skyrizi 49% vs 38% on ACR50 in PsA head-to-head. Trump bought up to $680K in Eli Lilly stock while admin promoted obesity drugs. Maryland caps Ozempic payments. Amgen Tavneos linked to 20 deaths in Japan. Relay zovegalisib Phase 2 data beats expectations. Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma

en-us

00:10:40

May 18, 2026 | Regeneron LAG-3 Phase 3 Failure...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/19

Regeneron's fianlimab misses PFS endpoint in melanoma, erasing ~$8B in market cap. Supreme Court rejects IRA pricing challenges from six pharma companies. FDA approves AstraZeneca's first-in-class Baxfendy for hypertension. Merck's sac-TMT scores Phase 3 dual-endpoint win.Visit us at www.thepharmacloseput.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, fianlimab, LAG-3, melanoma, REGN, Keytruda, pembrolizumab,

en-us

00:09:56

May 15, 2026 | FDA's CDER Chief Høeg Expected to...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/17

Three top FDA positions now in temporary hands as CDER's Høeg follows Makary out the door. Roche's Tecentriq wins ctDNA-guided bladder cancer approval with 36% DFS and 41% OS risk reductions paired with Natera's Signatera diagnostic. Plus Enhertu's early breast cancer expansion, Rigel's $85M Veppanu deal, Biogen's tau gamble, and oral Wegovy's first prescription decline.Visit is at www.thephamacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma

en-us

00:10:37

May 14, 2026 | AstraZeneca Imfinzi Phase 3 Win in...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/05/15

AstraZeneca's VOLGA trial hits EFS and OS incisplatin-ineligible bladder cancer, putting Imfinzi squarely in Keytruda's lane. Plus: Regenxbio's Duchenne gene therapy heads for FDA filing amid safetysignals, a brain tumor linked to a viral vector raises AAV concerns, and biopharma rallies behind Richard Pazdur for FDA commissioner. Also: BMS-Hengrui$15.2B alliance, BeOne's Beqalzi challenges Venclexta, and Taiho's Inqovi expands into AML.visit us at

en-us

121 results

Similar Podcasts

Mothman Podcast

Mothman Podcast

Autobiography of an Electron

Charles R. Gibson

This is a Science Show

Dustin Driver

Get Into Gate: A Stargate Podcast

Get Into Geek

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group